The financing significantly strengthens the company’s capital position as it expands U.S. commercial infrastructure and advances clinical evidence generation across its endovascular catheter platform.
March 16, 2026
The financing significantly strengthens the company’s capital position as it expands U.S. commercial infrastructure and advances clinical evidence generation across its endovascular catheter platform.